Brief: Biomea Fusion To Present Late Breaking Data From Ongoing Phase II Trial, Covalent-111, Evaluating Bmf-219 In Patients With Type 2 Diabetes, At The ADA 83rd Scientific Sessions 2023 In June
19/04/2023 13:32
April 19 (Reuters) - Biomea Fusion Inc BMEA.O :
* BIOMEA FUSION TO PRESENT LATE BREAKING DATA FROM ONGOING
PHASE
II TRIAL, COVALENT-111, EVALUATING BMF-219 IN PATIENTS WITH TYPE
2 DIABETES, AT THE ADA 83RD SCIENTIFIC SESSIONS 2023 IN JUNE
Source text for Eikon: ID:nGNX5yvTls
Further company coverage: BMEA.O
Recent news on Biomea Fusion
See all newsUS RESEARCH ROUNDUP-BlackRock, Microsoft, TransDigm Group
Brief: Biomea Fusion Announces Phase 1 Results For Bmf-650, Its Investigational Next-Generation Oral Small Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion To Announce Phase I Results For Bmf-650, Its Next-Generation Oral Small-Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion Announces Termination Of Proposed Public Offering Of Securities
Brief: Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes